Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC)

被引：0
|
作者：
Pujade-Lauraine, Eric
Weber, Beatrice E.
Ray-Coquard, Isabelle
Vergote, Ignace
Selle, Frederic
Del Campo, Jose Maria
Sufliarsky, Jozef
Tschoepe, Inga
Chesa, Pilar Garin
Nazabadioko, Serge
Pilz, Korinna
Joly, Florence
机构：
[1] Hop Hotel Dieu, AP HP, Unite Oncol Med, F-75181 Paris, France
[2] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
[5] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium
[6] Hop Tenon, F-75970 Paris, France
[7] Vall dHebron Inst Oncol, Barcelona, Spain
[8] Natl Canc Inst, Bratislava, Slovakia
[9] Boehringer Ingelheim GmbH & Co KG, Reims, France
[10] Boehringer Ingelheim GmbH & Co KG, Vienna, Austria
[11] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[12] Ctr Francois Baclesse, F-14021 Caen, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5504
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase II Trial of Fixed-Dosed Rate Gemcitabine in Platinum-Resistant Ovarian Cancer
    Ojeda Gonzalez, Belen
    Gonzalez Martin, Antonio
    Bover Barcelo, Isabel
    Fabregat i Mayol, Xavier
    Mellado, Begona
    Rubio Perez, Maria Jesus
    Alonso Carrion, Lorenzo
    Casado Herraez, Antonio
    Calvo Garcia, Elisa
    Churruca Galaz, Cristina
    Arcusa Lanza, Angels
    Herrero Ibanez, Ana
    Cebrian, Encarna Adrover
    Velasco, Andres Poveda
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (05): : 481 - 487
  • [22] Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
    Lyon, Kristopher A.
    Huang, Jason H.
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2164 - 2167
  • [23] FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
    Moore, Kathleen N.
    Vergote, Ignace
    Oaknin, Ana
    Colombo, Nicoletta
    Banerjee, Susana
    Oza, Amit
    Pautier, Patricia
    Malek, Karim
    Birrer, Michael J.
    FUTURE ONCOLOGY, 2018, 14 (17) : 1669 - 1678
  • [24] Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
    Kristina Lindemann
    Emma Gibbs
    Elisabeth Åvall-Lundqvist
    Rene dePont Christensen
    Kathrine Woie
    Marten Kalling
    Annika Auranen
    Seija Grenman
    Thomas Hoegberg
    Per Rosenberg
    Tone Skeie-Jensen
    Elisabet Hjerpe
    Anne Dørum
    Val Gebski
    Gunnar Kristensen
    British Journal of Cancer, 2017, 116 : 455 - 463
  • [25] Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
    Mansouri, Anita
    McGregor, Naomi
    Dunn, Rachel
    Dobbie, Sam
    Holmes, Jane
    Collins, Linda
    Nicum, Shibani
    BMJ OPEN, 2021, 11 (01):
  • [26] Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
    Lindemann, Kristina
    Gibbs, Emma
    Avall-Lundqvist, Elisabeth
    Christensen, Rene dePont
    Woie, Kathrine
    Kalling, Marten
    Auranen, Annika
    Grenman, Seija
    Hoegberg, Thomas
    Rosenberg, Per
    Skeie-Jensen, Tone
    Hjerpe, Elisabet
    Dorum, Anne
    Gebski, Val
    Kristensen, Gunnar
    BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 455 - 463
  • [27] Phase II trial of oncolytic vaccinia virus primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC) (NCT02759588)
    Holloway, R. W.
    Mendivil, A. A.
    Kendrick, J. E.
    Abaid, L. N.
    Brown, J. V.
    Fitzsimmons, C. K.
    Kennard, J. A.
    King, M.
    LeBlanc, J.
    Lopez, K.
    Manyam, M.
    McKenzie, N. D.
    Mori, K. M.
    Stephens, A. J.
    Ahmad, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S628 - S628
  • [28] Temsirolimus in platinum-resistant metastatic urothelial cancer: A phase II trial
    Gerullis, Holger
    Eimer, Christoph
    Georgas, Evangelos
    Bangner, Jens Willem
    Otto, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [29] Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Dana M. Roque
    Eric R. Siegel
    Natalia Buza
    Stefania Bellone
    Dan-Arin Silasi
    Gloria S. Huang
    Vaagn Andikyan
    Mitchell Clark
    Masoud Azodi
    Peter E. Schwartz
    Gautam G. Rao
    Jocelyn C. Reader
    Pei Hui
    Joan R. Tymon-Rosario
    Justin Harold
    Dennis Mauricio
    Burak Zeybek
    Gulden Menderes
    Gary Altwerger
    Elena Ratner
    Alessandro D. Santin
    British Journal of Cancer, 2022, 126 : 1695 - 1703
  • [30] Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Roque, Dana M.
    Siegel, Eric R.
    Buza, Natalia
    Bellone, Stefania
    Silasi, Dan-Arin
    Huang, Gloria S.
    Andikyan, Vaagn
    Clark, Mitchell
    Azodi, Masoud
    Schwartz, Peter E.
    Rao, Gautam G.
    Reader, Jocelyn C.
    Hui, Pei
    Tymon-Rosario, Joan R.
    Harold, Justin
    Mauricio, Dennis
    Zeybek, Burak
    Menderes, Gulden
    Altwerger, Gary
    Ratner, Elena
    Santin, Alessandro D.
    BRITISH JOURNAL OF CANCER, 2022, 126 (12) : 1695 - 1703
12345